O emprego da metodologia de superfície de resposta no desenvolvimento de um novo produto simbiótico, fermentado com Enterococcus faecium CRL 183 e Lactobacillus helveticus ssp jugurti 416, à base de extratos aquosos de soja e de Yacon (Smallanthus sonchifolius)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Avaliação do simbiótico fermentado com Enterococcus faecium CRL 183 e Lactobacillus helveticus ssp jugurti 416, à base de extratos aquosos de soja e de yacon (Smallanthus sonchifolius) no controle do desenvolvimento do Diabetes Mellitus

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Avaliação in vitro de caracteristicas probióticas do enterococcus faecium CRL 183 e do Lactobacillus helveticus ssp jugurti 416

Pós-graduação em Alimentos e Nutrição - FCFAR

A potential synbiotic product improves the lipid profile of diabetic rats

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Efeitos imunológicos da ingestão do produto de soja fermentado em ratos induzidos quimicamente com câncer de cólon

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Modulação da resposta imune através do consumo de produto probiótico de soja durante o desenvolvimento de câncer de mama murino experimental

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Intake of isoflavone-supplemented soy yogurt fermented with Enterococcus faecium lowers serum total cholesterol and non-HDL cholesterol of hypercholesterolemic rats

The aim of this study was to obtain an isoflavone-supplemented soy yogurt, fermented with Enterococcus faecium CRL 183 and Lactobacillus helveticus ssp jugurti, with suitable sensory properties and to assess the effects of the final product on blood lipids in hypercholesterolemic rats. Four isoflavone supplementation procedures were tested, in which the isoflavone was added at these stages: (1) before heat-treatment; (2) after heating and before fermentation; (3) after fermentation and (4) in the okara (by-product of soy milk) flour stirred into the fermented product when consumed. The products were subjected to a test of sensory acceptability. To assess their potential hypocholesterolemic properties in vivo, four groups of rats were used: control (C), hypercholesterolemic (H), hypercholesterolemic plus fermented product (HF) and hypercholesterolemic plus isoflavone-supplemented fermented product (HFI). Hypercholesterolemia was induced in rats of groups H, HF and HFI by feeding them on a commercial rat chow to which cholesterol and cholic acid had been added. Total, HDL and non-HDL cholesterol and triglycerides were measured in the blood of the rats. No significant sensorial differences were detected among the samples of soy yogurt supplemented with isoflavones at various processing stages. Rats fed a fermented soy product enriched with isoflavones (HFI group) had significantly (P < 0.05) less serum total cholesterol (15.5%) compared with rats fed a hypercholesterolemic diet (H group). Non-HDL cholesterol was less (P < 0.05) in rats fed a fermented soy product enriched or not with isoflavones (27.4 and 23.2%) compared to H group. The HDL-C and triglyceride concentrations did not differ significantly among the groups. It was possible to obtain an isoflavone-supplemented soy yogurt with satisfactory sensory characteristics. The resulting supplemented soy yogurt was capable of producing a lipid-lowering effect in hypercholesterolemic rats, relative to the animals that did not consume this product.

Aspectos sensoriais e físico-químicos de “iogurtes” de soja com espessantes/estabilizantes a base de fécula de inhame (Dioscorea alata), amido modificado e gelatina

This study had as objective to evaluate the effect of yam starch, modified starch from Cargill-Brasil (Amidomax 4800 (R)) and gelatin from Gelita-Brasil (GEL-LAC) as stabilizers/thickeners in different ratios and combinations in the soy yoghurt fermented with Enterococcus faecium and Lactobacillus helveticus ssp jugurti. Ten soy yoghurt formulations containing these different stabilizers/thickeners, always totalizing 0.5% in relation to the final formulation, were analyzed in sensorial and physical-chemical terms. Based on the observed results, it was concluded in relation to the sensorial point of view that the more appropriate product was processed only with gelatin at 0.5% concentration. This product also presented the best physical-chemical results related to consistency, syneresis and water holding capacity. However, the isolated use of gelatin increased fermentation time of the soy yoghurt.

Optimization of a synbiotic formulation of soy yoghurt containing yacon extract by response surface methodology

A synbiotic yoghurt based on a combination of soymilk and yacon water extract (from yacon root tubers) was developed as a novel food product fermented with a probiotic culture of Enterococcus faecium CRL 183 and Lactobacillus helveticus ssp jugurti 4l6. Response surface methodology (RSM) was used to optimize the independent variables soymilk protein concentration and percentage of yacon extract in the formulation through a Central Composite Rotatable Design (CCRD), consisting of a 22 factorial design with two levels (-1, +1), two central points (0) and four axial points (± a, 0) (0, ± α). The responses were assessed by consumer acceptance tests. The optimization indicated that a formulation with a soymilk protein concentration of 1.74g/L and 25.86% of yacon extract gave the best average values, 5.91 for the taste and 6.00 for the overall impression responses. The formulation with 40% of yacon extract and the same concentration of soymilk protein achieved similar acceptance values: taste (5.94) and overall impression (5.87), however, with the extra yacon, it probably had a greater content of prebiotic fructooligosaccharides. Consequently, both formulations may give useful functional foods, with sensory properties comparable with those of soy yoghurt (control formulation). Copyright © 2010 by New Century Health Publishers.

Aspectos sensoriais e físico-químicos de iogurtes de soja com espessantes/estabilizantes à base de fécula de inhame (Dioscorea alata), amido modificado e gelatina

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Efeito da adição de inulina no crescimento, resistência gastrintestinal e capacidade de remoção de colesterol de Lactobacillus helveticus 416 e Enterococcus faecium CRL 183

O objetivo do presente estudo foi verificar o efeito da adição de um prebiótico nas características de crescimento, resistência às condições do trato gastrintestinal e remoção de colesterol in vitro, das cepas de Enterococcus faecium CRL183 e Lactobacillus helveticus 416. A fonte de prebiótico foi composta por Inulina GR – Orafti, sendo testadas as seguintes concentrações: 1,0%, 2,0%, 3,0%; 4,0%; 5,0% e 6,0% p/v). Para a avaliação da resistência às condições do trato gastrintestinal, os microrganismos foram colocados em contato com um fluido gástrico simulado por 2 horas (9g/L de NaCl, 3g/L de pepsina, pH 1,8) e com um fluido intestinal simulado por 3 horas (0,9g/L de pancreatina, 12,5g/L de bicarbonato de sódio e 6,0 g/L de Oxgall). Após o período de contato com os fluidos, foram realizadas diluições seriais e plaqueamento em meios específicos. No estudo de redução de colesterol, meios de cultura contendo inulina e colesterol (1%) foram inoculados com as cepas probióticas e incubados em anaerobiose a 37°C/24h. A capacidade de redução do colesterol foi determinada pela diferença entre a concentração de colesterol adicionada ao meio de cultura e a de colesterol residual. Os resultados foram submetidos à análise de variância e teste de médias de Tukey (p≤0,05). A adição de inulina não resultou em alteração no ciclo logarítmico de crescimento dos microrganismos. Porém, quando os dados foram submetidos à análise estatística, constatou-se que a adição de 1% a 4% de inulina inibiu o crescimento de Lactobacillus helveticus 416, sendo que para as concentrações de 5% a 6% estas alterações não foram perceptíveis. A cepa de Enterococcus faecium CRL 183 apresentou crescimento superior na presença de 2% e 4% de inulina. Após o contato com o fluido gástrico simulado, observou-se redução de 1 ciclo logarítmico no crescimento da cepa... (Resumo completo, clicar acesso eletrônico abaixo)

Blood pressure lowering effects of Lactobacillus helveticus fermented milk containing bioactive peptides Ile-Pro-Pro and Val-Pro-Pro; mechanistic, kinetic and clinical studies

The purpose of the present study was to evaluate the effects of Lactobacillus helveticus fermented milk (peptide milk) containing the casein-derived tripeptides Isoleucyl-prolyl-proline (Ile-Pro-Pro) and Valyl-prolyl-proline (Val-Pro-Pro) on blood pressure and vascular function in hypertensive subjects. The peptide milk lowered systolic and diastolic blood pressure in long-term use in hypertensive subjects when blood pressure was measured by using 24-hour ambulatory blood pressure measurement (ABPM). The blood pressure lowering effect was seen with the dose of 50 mg of tripeptides, and a tendency for lowering blood pressure was also observed when the dose was 5 mg. No adverse effects compared to the placebo group were reported or detected in laboratory analysis. The effect of the peptide milk on arterial stiffness was shown using two different methods, the ambulatory arterial stiffness index (AASI) and pulse wave analysis (PWA). According to the AASI, arterial stiffness was significantly reduced in the peptide milk group compared to the baseline level, but the difference was not significant compared to the placebo group. PWA showed that the peptide milk reduced arterial stiffness significantly compared to the placebo group. Endothelium-independent relaxation (nitroglycerin) and endothelium-dependent relaxation (salbutamol) did not differ between the groups. The blood pressure lowering mechanisms of the tripeptides and the kinetics of Ile-Pro-Pro were investigated using spontaneously hypertensive rats (SHR) and Sprague-Dawley rats. Previous studies have suggested that the blood pressure lowering effect of the tripeptides Ile-Pro-Pro and Val-Pro-Pro is based on angiotensin-converting enzyme inhibition, but the present findings did not agree with these previous studies. It was shown in SHR that calcium, potassium and magnesium may also have an important role in attenuating the development of hypertension as part of the peptide milk effect. In addition, the present study suggests indirectly that improved endothelial nitric oxide release capacity is not the mechanism by which peptide milk mediates its favourable circulatory effects. The kinetics of Ile-Pro-Pro were studied using adult Sprague-Dawley rats. The results showed that orally administered Ile-Pro-Pro is absorbed at least partly intact from the gastrointestinal tract. Radiolabelled Ile-Pro-Pro was distributed in different tissues and considerable radioactivity levels were found in tissues related to the renin-angiotensin system (RAS), adrenals, aorta and kidneys. Ile-Pro-Pro does not bind to plasma proteins, and therefore it is possible that its blood pressure lowering effect is mediated by free Ile-Pro-Pro. In conclusion, consumption of the peptide milk lowers blood pressure and reduces arterial stiffness in hypertensive subjects. Ile-Pro-Pro can be absorbed partly intact from the gastrointestinal tract and might accumulate in tissues related to the RAS. The precise blood pressure lowering mechanism of peptide milk remains to be studied.

Lactobacillus helveticus R0052 et Bifidobacterium longum R0175 en combinaison réduisent l’apoptose dans le système limbique après ischémie myocardique transitoire chez le rat

Nous avons démontré la présence d'apoptose dans le système limbique suivant un infarctus du myocarde. Cette mort cellulaire serait partiellement reliée à l'augmentation de cytokines pro-inflammatoires. Des études démontrent que certains probiotiques ont des effets bénéfiques en diminuant le ratio de cytokines pro/anti-inflammatoires. La prise de probiotiques en prévention, avant l’occlusion d’une artère coronarienne, pourrait-elle diminuer l’apoptose dans le système limbique? Méthodes : La combinaison de probiotiques Lactobacillus helveticus R0052 et Bifidobacterium longum R0175 ou son véhicule fut additionné dans l’eau des rats pendant 28 jours consécutifs. Un infarctus du myocarde fut provoqué par l’occlusion de l’artère coronaire gauche. Après 40 minutes d'occlusion, les régions ischémiques ont été reperfusées pour 72 heures. Les animaux furent sacrifiés et la taille de l'infarctus mesurée. L'amygdale et l'hippocampe furent prélevés pour déterminer l'activité de la caspase-3 (pro-apoptotique), le ratio Bax/Bcl2(proapoptotique/ anti-apoptotique) et l'activité d'Akt (survie cellulaire). Résultats : La taille de l’infarctus n'est pas diminuée dans le groupe probiotique (45% de la région à risque)comparé au groupe placebo. Nos marqueurs d’apoptose démontrent une diminution dans les régions du gyrus denté, de l’amygdale latérale et médiane dans le groupe probiotique par rapport au placebo. L’activité de la caspase-3 et le ratio Bax:Bcl2 furent réduits dans le groupe probiotique de 50% et 40% respectivement (p < 0.05) et phosphorylation d’Akt fut augmentée de 35% (p<0.05). Aucune différence fut observée pour les régions Ca1 et Ca3. Conclusion : La combinaison de probiotiques utilisée réduit l’apoptose dans différentes régions du système limbique 72 heures après un IM.

Effet des probiotiques Lactobacillus helveticus RO052 et Bifidobacterium longum RO175 sur la dépression post-infarctus du myocarde chez le rat

Nous avons déjà démontré que les probiotiques réduisaient l'apoptose observée dans le système limbique après un infarctus du myocarde (IM), suggérant un rôle anti-dépresseur potentiel des probiotiques. Cette étude a été conçue pour déterminer si les probiotiques pouvaient atténuer le comportement dépressif observé après un infarctus du myocarde. Un autre objectif visait à démontrer qu’une altération de la barrière intestinale pourrait avoir lieu lors d’un IM et que les probiotiques pourraient empêcher cette altération de la perméabilité intestinale. Méthodes: Des rats mâles Sprague-Dawley ont reçu des probiotiques (1 milliard de cellules bactériennes vivantes de Lactobacillus helveticus R0052 et Bifidobacterium longum R0175) ou le véhicule tous les jours en dilution dans leur eau, débutant 1 semaine avant l'induction d'une ischémie myocardique. Un infarctus a ensuite été induit chez la moitié des rats, par l'occlusion de l'artère coronaire antérieure gauche (40 minutes) suivie d'une reperfusion. Les rats témoins, l'autre moitié de la cohorte, ont été soumis à la même procédure sans occlusion coronarienne. Une semaine après l'infarctus, les animaux ont été resoumis au traitement préalable jusqu'au moment du sacrifice. Le comportement dépressif a été évalué par trois tests soit: l'interaction sociale, le test de nage forcée et le test d'évitement passif. Résultats: Les résultats obtenus indiquent qu'en absence d'infarctus, les probiotiques n'ont pas d'effet significatif. Toutefois, en dépit de taille similaire IM, des rats traités avec des probiotiques, ont démontré davantage d'interactions sociales et une meilleure performance dans le test de nage forcée et d'évitement passif, comparativement à des rats du groupe IM sans probiotique (p<0,05). Conclusion: Les probiotiques atténuent le comportement dépressif observé après infarctus du myocarde par un mécanisme qui pourrait impliquer l'intégrité des intestins.